Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting...
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early...
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.41 | 7.00256191289 | 5.855 | 6.58 | 5.74 | 1762937 | 6.10587243 | CS |
4 | -0.785 | -11.134751773 | 7.05 | 7.6299 | 5.46 | 1406575 | 6.34435265 | CS |
12 | -3.63 | -36.6851945427 | 9.895 | 11.4 | 5.46 | 1749794 | 8.23372108 | CS |
26 | 0.115 | 1.86991869919 | 6.15 | 11.4 | 5.46 | 1641514 | 8.10318586 | CS |
52 | 0.515 | 8.95652173913 | 5.75 | 11.4 | 4.32 | 1226068 | 7.54391625 | CS |
156 | -1.315 | -17.3482849604 | 7.58 | 14.0435 | 1.45 | 652768 | 7.43280496 | CS |
260 | -10.685 | -63.0383480826 | 16.95 | 28.36 | 1.45 | 533078 | 7.84304338 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관